RaQualia Pharma Inc. (4579.T)
JPY 418.0
(0.24%)
JPY 418.0
(0.24%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.81 Billion JPY | -0.12% |
| 2022 | 1.82 Billion JPY | 4.15% |
| 2021 | 1.74 Billion JPY | 20.09% |
| 2020 | 1.45 Billion JPY | -0.05% |
| 2019 | 1.45 Billion JPY | -15.84% |
| 2018 | 1.73 Billion JPY | 21.84% |
| 2017 | 1.42 Billion JPY | 5.39% |
| 2016 | 1.34 Billion JPY | -32.96% |
| 2015 | 2.01 Billion JPY | -13.91% |
| 2014 | 2.33 Billion JPY | -1.3% |
| 2013 | 2.36 Billion JPY | -11.26% |
| 2012 | 2.66 Billion JPY | 2.95% |
| 2011 | 2.58 Billion JPY | 6.53% |
| 2010 | 2.43 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 498.39 Million JPY | -4.94% |
| 2024 Q2 | 748.31 Million JPY | 59.46% |
| 2023 Q4 | 524.3 Million JPY | 5.08% |
| 2023 FY | 1.81 Billion JPY | -0.12% |
| 2023 Q1 | 419.88 Million JPY | -28.24% |
| 2023 Q2 | 495.29 Million JPY | 17.96% |
| 2023 Q3 | 498.97 Million JPY | 0.74% |
| 2022 Q1 | 405.9 Million JPY | -18.93% |
| 2022 FY | 1.82 Billion JPY | 4.15% |
| 2022 Q4 | 585.12 Million JPY | 31.8% |
| 2022 Q3 | 443.96 Million JPY | 15.25% |
| 2022 Q2 | 385.23 Million JPY | -5.09% |
| 2021 Q1 | 465.03 Million JPY | 22.91% |
| 2021 Q2 | 365.84 Million JPY | -21.33% |
| 2021 Q4 | 500.67 Million JPY | 20.31% |
| 2021 Q3 | 416.15 Million JPY | 13.75% |
| 2021 FY | 1.74 Billion JPY | 20.09% |
| 2020 Q3 | 358.68 Million JPY | 3.32% |
| 2020 FY | 1.45 Billion JPY | -0.05% |
| 2020 Q2 | 347.15 Million JPY | -6.47% |
| 2020 Q1 | 371.16 Million JPY | -2.15% |
| 2020 Q4 | 378.35 Million JPY | 5.48% |
| 2019 FY | 1.45 Billion JPY | -15.84% |
| 2019 Q3 | 358.99 Million JPY | 1.37% |
| 2019 Q4 | 379.32 Million JPY | 5.66% |
| 2019 Q1 | 363.64 Million JPY | -12.92% |
| 2019 Q2 | 354.14 Million JPY | -2.61% |
| 2018 FY | 1.73 Billion JPY | 21.84% |
| 2018 Q4 | 417.59 Million JPY | 22.18% |
| 2018 Q1 | 617.49 Million JPY | 58.24% |
| 2018 Q2 | 353.33 Million JPY | -42.78% |
| 2018 Q3 | 341.79 Million JPY | -3.27% |
| 2017 Q1 | 363.28 Million JPY | 3.5% |
| 2017 FY | 1.42 Billion JPY | 5.39% |
| 2017 Q4 | 390.23 Million JPY | 16.08% |
| 2017 Q3 | 336.17 Million JPY | 1.75% |
| 2017 Q2 | 330.37 Million JPY | -9.06% |
| 2016 Q2 | 305.3 Million JPY | -16.87% |
| 2016 FY | 1.34 Billion JPY | -32.96% |
| 2016 Q1 | 367.27 Million JPY | -15.25% |
| 2016 Q3 | 323.92 Million JPY | 6.1% |
| 2016 Q4 | 350.98 Million JPY | 8.36% |
| 2015 Q3 | 582.8 Million JPY | 11.92% |
| 2015 FY | 2.01 Billion JPY | -13.91% |
| 2015 Q1 | 473.21 Million JPY | -34.13% |
| 2015 Q2 | 520.74 Million JPY | 10.05% |
| 2015 Q4 | 433.33 Million JPY | -25.65% |
| 2014 FY | 2.33 Billion JPY | -1.3% |
| 2014 Q4 | 718.4 Million JPY | 35.58% |
| 2014 Q3 | 529.89 Million JPY | -2.39% |
| 2014 Q2 | 542.86 Million JPY | -0.16% |
| 2014 Q1 | 543.74 Million JPY | -9.66% |
| 2013 Q1 | 567.1 Million JPY | -16.83% |
| 2013 Q4 | 601.86 Million JPY | 9.85% |
| 2013 Q3 | 547.92 Million JPY | -15.55% |
| 2013 Q2 | 648.81 Million JPY | 14.41% |
| 2013 FY | 2.36 Billion JPY | -11.26% |
| 2012 Q3 | 653.97 Million JPY | -2.6% |
| 2012 Q1 | 658.58 Million JPY | 5.53% |
| 2012 FY | 2.66 Billion JPY | 2.95% |
| 2012 Q4 | 681.88 Million JPY | 4.27% |
| 2012 Q2 | 671.43 Million JPY | 1.95% |
| 2011 Q3 | 793.25 Million JPY | 35.82% |
| 2011 FY | 2.58 Billion JPY | 6.53% |
| 2011 Q4 | 624.04 Million JPY | -21.33% |
| 2011 Q1 | 588.03 Million JPY | 0.0% |
| 2011 Q2 | 584.05 Million JPY | -0.68% |
| 2010 FY | 2.43 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -41.533% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -215.17% |
| GNI Group Ltd. | 9.32 Billion JPY | 80.499% |
| Linical Co., Ltd. | 2.7 Billion JPY | 32.798% |
| Trans Genic Inc. | 2.15 Billion JPY | 15.829% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -21.915% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 40.804% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 2.102% |
| AnGes, Inc. | 8.9 Billion JPY | 79.579% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -92.767% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 90.527% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -340.192% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -86.385% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 29.196% |
| CanBas Co., Ltd. | 278 Million JPY | -553.939% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -59.255% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -13.355% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 23.425% |
| PeptiDream Inc. | 9.68 Billion JPY | 81.234% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 7.275% |
| Ribomic Inc. | 1.1 Billion JPY | -64.418% |
| SanBio Company Limited | 4.53 Billion JPY | 59.948% |
| Healios K.K. | 3.48 Billion JPY | 47.865% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -57.434% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -36.231% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -29.533% |
| StemRIM | 2.07 Billion JPY | 12.43% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 7.413% |
| FunPep Company Limited | 313.82 Million JPY | -479.295% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -89.763% |
| Stella Pharma Corporation | 963.98 Million JPY | -88.587% |
| TMS Co., Ltd. | 943.25 Million JPY | -92.732% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -66.792% |
| Cuorips Inc. | 598.11 Million JPY | -203.945% |
| K Pharma,Inc. | 543.94 Million JPY | -234.218% |
| Takara Bio Inc. | 23.9 Billion JPY | 92.395% |
| ReproCELL Incorporated | 1.51 Billion JPY | -20.075% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -53.544% |
| StemCell Institute Inc. | 1.16 Billion JPY | -56.434% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -19.423% |
| CellSeed Inc. | 804.93 Million JPY | -125.852% |